ASX Announcement
30 January 2024

Q2 FY24 Quarterly Investor Presentation

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to provide its Q2 FY24 Investor Presentation to be delivered at the Quarterly Investor Webinar held with CEO Dr Luke Reid and SVP, Therapeutics Prof Trent Munro at 10:00am AEST / 11.00am AEDT today.

Presenting: Microba CEO, Dr Luke Reid and SVP Therapeutics Prof. Trent Munro
Time: 10:00am AEST / 11:00am AEDT today, Tuesday 30 January 2024

To register for the Quarterly Investor Webinar please click the link below. Investors can submit questions prior to the webinar to investor@microba.com or do so via the Zoom Q&A function during the webinar.

Microba Q2 FY24 Investor Webinar Registration

This announcement has been authorised for release by the Board of Directors

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Investor / Media Relations
E: investor@microba.com
W: https://ir.microba.com/
Join our Investor Mailing List

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

MICROBA™

Transforming health through the human microbiome

Q2 FY24 Results

30 January 2024

Disclaimer

This presentation (**Presentation**) has been prepared by Microba Life Sciences Limited (**Microba**).

Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.

Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.

Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba's views on its future financial condition and/or performance.

Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.

Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation.

Two core business segments driven by a proprietary databank

Services	Databank	Therapeutics

Customer Testing

Microba provides testing and data analysis for a fee to clinicians, consumers and research customers

Data

Proprietary databank

- Health Data
- Biome Data

Driving discovery of novel therapeutic leads

Insights

Novel Therapies

Data-driven therapeutics platform developing novel monoclonal microbial cell therapies

Company Snapshot

Continuous YoY revenue growth over 5 years of operations

Partnerships with market leaders incl. **Sonic Healthcare** (ASX: SHL), **Ginkgo Bioworks** (NYSE: DNA), **SYNLAB** (GR:SYAB) + more

Large, unique, proprietary microbiome databank

3 key therapeutic programs with successful **Phase I clinical trial** for lead IBD

World-leading technology in the emerging and rapidly growing **US$4.9 billion** microbiome sector[1]

Globally **leading microbiome expertise** complemented by drug discovery experts including Prof. Ian Frazer

[1] Frost & Sullivan market report – Growth Opportunities in Human Microbiome Market Forecast to 2023 – Prepared November 2019

Recent Milestones

SUCCESSFUL UK ACQUISITION

invivo®

Successful acquisition of United Kingdom microbiome testing company, Invivo Clinical.

- *a leading microbiome test provider for healthcare professionals in the UK*
- *established customer base of over 1,700 active healthcare professionals*
- *more than 20,000 microbiome tests sold since 2020*
- *evidence based supplement portfolio*
- *Unaudited sales in H1 FY24 totalled $4.39m AUD*
- *has been self-funded from cashflow with no external capital required and has been consistently operating cashflow positive*

SUCCESSFUL PHASE I CLINICAL TRIAL FOR IBD LEAD DRUG CANDIDATE

Phase I Clinical Trial of Microba's lead therapeutic candidate MAP 315 successfully completed, demonstrating it is safe and well tolerated.

- *favourable safety and tolerability profile across both low and high dose cohorts.*
- *no clinically significant safety signals*
- *all participants completed the study and all dosing.*
- *faecal kinetics by metagenomic analysis indicates successful delivery into the gastrointestinal tract*
- *results provide strong positive support for continuing to advance the clinical development of MAP 315 for the treatment of Ulcerative Colitis*

2ND ALLERGY PROGRAM AGREEMENT SIGNED

Agreement signed with IFF (NYSE: IFF) to develop novel microbiome-based treatments for multiple forms of allergy

- *second agreement between Microba and IFF*
- *first agreement in 2021 saw the identification of lead species, and IFF has now selected a number of species to move forward into Stage 2.*
- *Stage 2 project will complete isolation and characterisation of strains selected from Stage 1 and characterisation of those strains.*
- *Upfront payment to Microba of AUD $924k and has exclusive option to license for commercialization, which if executed may result in future royalty payments to Microba.*

Microbiome Services
Driving global revenues and data growth

Q2 Financial Highlights – Strong revenue growth

- Growth in MetaXplore translating into strong sales and revenue growth
- Major partner SYNLAB, Europe's largest medical diagnostic company, revenues up 115% YoY
- UK acquisition, Invivo Clinical, revenue contribution from 5 to 31 December





*FY24 numbers on this slide represent unaudited revenue and include Invivo figures from 5 – 31 December 2023.

Advanced microbiome testing addressing large markets in healthcare

Addressable Healthcare Markets

Gastrointestinal disorders	Gastrointestinal infection
MetaXplore™	MetaPanel™
Is the microbiome contributing to the patients DGBI and how can they manage?	Does the patient have a pathogen and how can I selectively treat it?
150M est. addressable patients worldwide[1]	**16M est.** addressable patients worldwide[2]
Well established out of pocket private pay market	Well established hospital direct-bill and path to reimbursement

[1]Estimated based on the prevalence of specific Disorders of the Gut-Brain Interaction across 26 countries (Av prevalence of 32.8% DOI: 10.1111/nmo.14594), and the proportion regularly seeking medical support with one or more doctor visit per month (Average 15.4% - DOI: 10.1053/j.gastro.2020.04.014)

[2] Estimated based on the global number of immuno-compromised patients and other patients at high risk for gastrointestinal infection (>8.1m chemotherapy treated solid tumor cancer patients and >1.1m haematological cancer patients DOI: https://doi.org/10.1016/S1470-2045(19)30163-9), (>3m dialysis patients DOI: 10.1038/s41581-022-00542-7), (>140k Organ Transplant patients per year https://www.transplant-observatory.org/), (>3.5m long stay ICU patients – estimate based on data from https://ourworldindata.org/grapher/intensive-care-beds-per-100000)

Significant international distribution

Partners provides access into 35 countries with 17 now operational

Strategic acquisition unlocking a geographical base and laboratory in the UK, supporting the next phase of Microba's international growth strategy.



Operating Team and/or Laboratory Centre's

Contracted partner/s operational

Access via current distribution partners

| UK Strategic Acquisition

| Unlocking the UK market through a targeted acquisition

invivo®

- **UK microbiome company Invivo Clinical acquired in December 2023**
- Over 1,700 healthcare professional customers*
- Self-funded with positive operating cashflow
- Positioned for growth acceleration

Laboratory - Bristol

- 10 staff
- PCR laboratory
- CL2 laboratory

Headquarters - Stroud

- 23 staff
- Finance, sales and marketing
- Customer service & clinical support



Multiple growth opportunities and Microba synergies

- **Microba's MetaXplore test positioned to be delivered to Invivo customers** and expected to fuel growth in GI test uptake
- **Continued growth acceleration in Vaginal microbiome testing revenue** with 40% growth in FY23.
- **The integrative healthcare market is expanding** as clinicians move to private practice due to pressure on the NHS.
- Small sales team being expanded with significant opportunity to accelerate growth.

UNIVERSITY OF CAMBRIDGE UNIVERSITY OF LIVERPOOL Smith+Nephew

MICROBA

* FY23 saw over 1,700 ordering healthcare professional accounts

Strengthening Invivo's position in GI microbiome testing

A platform for UK market entry and growth of Microba's MetaXplore™ test

79%

of Invivo's **testing revenue** is through their GI products*

19%

growth in GI testing revenue in FY23

"From our leading position in market, we expect Microba's world leading MetaXplore™ will become the most favoured microbiome test for healthcare professionals in the UK" Debbie Cotton – Head of Clinical Innovation, Invivo

- **Current leading GI testing product for UK** healthcare professionals
- Featuring 7 host markers, 62 microbial markers
- Microbiome analysis via multiplex PCR
- Offers static PDF reports

- **Next generation advanced GI test** using Microba's world leading metagenomic technology
- Includes 7 host markers, 28,000 microbial markers, 19 microbiome functions
- Offers both static PDF and interactive digital reports.

MICROBA

* FY23 results

| Invivo Clinical H1 FY24 sales performance

H1 FY24
Key sales metrics

$4.39m
H1 Sales

49%
H1 Gross Margin

4,208
H1 Tests Sold

62,527
H1 Supplements Sold

United Kingdom Financial Year H1 FY24 runs from 1 April to 31 September 2023.

Microbiome Therapeutics

Developing novel monoclonal microbial cell therapies

Recent Program Highlights

Inflammatory Bowel Disease Program

MAP315 Phase I completed, product safe and well tolerated. Positive MOA data generated.

Trial completed and data confirms that MAP315 is safe and well tolerated. Data also indicates potential engraftment of MAP 315. Multi-modal mechanism of action (MOA) data generated for MAP315.

Immuno-Oncology Program

Confirmed potent anti-tumour activity.

Multiple mouse models have demonstrated that Microba's therapeutic leads can significantly reduce tumour burden. Further, immunological studies demonstrated activity consistent with induction of a specific and targeted immune response. Additional animal studies and immune profiling experiments are continuing to enable selection of a lead therapeutic candidate in H2 FY24.

Autoimmune Disease Program

Primary screening 100% complete.

Stage 1 activity screens complete with 62% of strains demonstrating significant immunomodulatory activity and a further 18% significantly impacting the inflammasome. 35 strains have now progressed into Stage 2 functional screening for expected completion in Q4 FY24 to enable lead candidate selection.

Precision Microbiome Therapeutics

- **Precision microbiome analysis platform** delivering unparalleled accuracy, coverage & depth.
- Data driven discovery platform utilising one of the worlds **most advanced & highly curated microbiome datasets.**
- Next generation approach to microbiome drug development **identifying and isolating single keystone species to develop Live Biotherapeutics.**

Novel Pipeline of Microbiome Therapies

✓ Potent and novel biology mediated by Live Biotherapeutic strategy

✓ Scalable GMP manufacturing process

✓ Oral delivery and Excellent safety profile

Microba Partners

Mount Sinai · University of Miami · Omico · Garvan Institute of Medical Research · Ginkgo Bioworks · The University Of Queensland Australia · mater · Bacthera · Centre for the Microbiome Research · iff

Experienced Leadership

Trent Munro
SVP Therapeutics

Prof Ian Frazer
Director & MAB Chair

Prof Gene Tyson
Co-Founder

Prof Phil Hugenholtz
Co-Founder

AMGEN · Nestlé · Massachusetts Institute of Technology · Queensland University of Technology · Harvard University · University of Cambridge · JGI · CSL · Roche · The University Of Queensland Australia

| Microba is Pioneering an Advanced AI/ML Approach to Development Next Generation Precision Live Biotherapeutics

Worlds most advanced bioinformatic pipeline for metagenomic microbiome analysis

Large human dataset w deep health metadata powering AI/ML* discovery

Repeatable pipeline of single strain live biotherapeutic candidates

Lead candidate MAP 315 safe and well tolerated in Phase I study with unique MOA

MAP 315 is Phase 2 ready for IBD (mild to moderate ulcerative colitis)

Identified oncology leads with checkpoint synergistic anti-tumour activity

Advanced candidate discovery program in auto-immune disease partnered with Ginkgo

Combines Human data driven leads with advanced high-throughput biodiscovery

MICROBA

* Artificial Intelligence (AI) and Machine Learning (ML)

Human data driven insights

Microbiome Databank

- Health Data
- Biome Data



Precision Microbiome Therapeutics

MICROBA

Big data powered therapeutics from the human microbiome



>60,000 metagenomes*
>1,000 health indicators/participant
>1M Genomes
>100M Genes
>100K species

>100TB of DNA data
8,000B alignments
200M CPU hours processing time
20K vCPUs, 50TB RAM

>9,000 isolated strains
>500 species isolated in total
>200 previously uncultured species isolated
1 Phase II ready asset
Multiple pre-clinical leads

MiCROBA

*Derived from both internal and external data

Therapeutic Pipeline



MiCROBA

• *Live Biotherapeutic Product (LBP)*

| **Advancing allergy treatment -** partnership with multi-national probiotics leader IFF

Stage 1 complete discovering therapeutic leads

- ✓ Nov 2021 Microba signed a therapeutic partnership with IFF to develop novel treatments for multiple forms of allergy
- ✓ Stage 1 leveraged Microba's data-driven drug discovery platform to identify multiple leads
- ✓ IFF subsequently executed their option to proceed into a Stage 2 agreement to further pursue those leads

Stage 2 signed to complete isolation and activity assessment

- The parties have now signed a Stage 2 agreement to isolate strains from the identified lead species, and complete primary characterisation of those strains
- IFF will pay €560k (Approx. AUD $920k) for the Stage 2 work
- IFF have an option to license the strains and intellectual property on commercial terms which may result in future royalties and milestone payments



IFF THE PROVEN LEADER IN PROBIOTICS

NYSE IFF **| Market cap** $19.6B* **| HQ** New York

IFF Achieves Industrial Scale Production of a Strict Anaerobic 'Next Generation' Probiotic Strain

Oegstgeest, The Netherlands – Mar. 16, 2023 – IFF—a leading global player in the health and wellbeing industry—today reveals it has achieved the successful production of a strict anaerobic 'next generation' probiotic strain at industrial scale. The remarkable milestone demonstrates IFF's unique capabilities in fermentation, downstream processing and formulation in this space. IFF's advancement in identifying new microbiome solutions and establishing safe and efficient production at industrial scale will ultimately support commercially viable innovation in the dietary supplement market in years to come.

"We've made this breakthrough achievement thanks to our cutting-edge process development capabilities—which encompass small-scale, high-throughput and high-information tools—paired with our large-scale manufacturing skills and deep investments in our teams, facilities and certifications," said Sebastian Stahl, director for Process R&D at IFF. "Not only does the successful production of Akkermansia at industrial scale demonstrate that we have the know-how and technologies to identify promising microbiome solutions, but we're also experts at establishing their safe and efficient production."

The production of a 'next generation' probiotic at scale is another cornerstone of IFF's strategy to refresh and deliver microbiome-science-based solutions through a mixture of strategic partnerships and investments in research and development and builds on the company's existing leadership in the areas of probiotics, prebiotics and botanical extracts.

"We are proud of this milestone in IFF's history, and we are confident in our ability to commercialize our extensive microbiome pipeline, comprising in-house developments, as well as projects with external partners or customers," said Sebastien Guery, vice president, Health, IFF.



*Accessed on 4 December 2023 from https://finance.yahoo.com/quote/IFF/

Inflammatory Bowel Disease Program

MAP 315 Proposed Mechanism of Action in IBD

Inflammatory Bowel Disease affects more that 6 million people globally.

Many of the current therapeutics suffer from poor compliance, undesirable side-effects and achieve low rates of mucosal healing.

MAP 315 is a safe, oral live biotherapeutic that promotes mucosal healing and immune homeostasis.





MAP 315 is safe and well tolerated in a Phase I clinical trial

Phase I Clinical trial of MAP 315 completed in Australia

- FDA pre-IND feedback positive
- Lead drug candidate MAP 315, demonstrated it is safe and well tolerated at both low and high doses in the Phase I, healthy volunteer clinical trial.
- Unblinded analysis of trial data demonstrated no clinically significant safety signals from assessments including ECGs and laboratory analysis of haematology, coagulation, clinical chemistry, urinalysis parameters, or impact on inflammatory biomarkers.
- Faecal kinetics assessed by metagenomic analysis indicated presence of MAP 315 at the terminal 28-day analysis timepoint, 14 days after the completion of dosing, confirming the ability to successfully deliver live MAP315 into the gastrointestinal tract.

Phase I trial details

- GMP Material produced with Bacthera
- Placebo controlled, double blind, healthy volunteer study
- Low and High dose via daily oral delivery for 2 weeks

Phase II trial planning Initiated

- Protocol development in final stages
- Study start timing currently being determined - Adaptive Patient Study, N = 140 to 200 examining induction of remission

MiCROBA Beyond DRUG DEVELOPMENT Nucleus Network BACTHERA

| Oncology Program

Our Oncology Leads Drive Potent Biology and May Turn Cold Tumours Hot

CD3



CD4



CD8



NK1.1



- Little or no increase in T cell infiltrate by ICI only (“responder” mice slightly higher)
- MH60 causes higher CD4 and CD8 infiltration
- MH62 causes higher CD4 infiltration

| Autoimmune Program

GINKGO BIOWORKS

Significant hit rate and potency observed in primary screens

Suppression of Th1 Immune Response



PBMC based immune suppression assay data showing suppression of IFNγ production

Inflammasome Suppression



Inflammasome activation assay in THP1 cells showing reduction in IL-1β

MICROBA

Microba is developing the 3rd Generation of Microbiome Therapeutics using a human data driven approach

1 First Generation

Fecal Doner Derived & FMT

FDA approval Nov 30 2022
Faeacal doner derived enema drug product

FDA approval April 27 2023
Faeacal doner derived oral capsule drug product

2 Second Generation

Bacterial Consortia

Vedanta Biosciences
Vedanta Biosciences Raises $106.5M in Funding

SER-155
Phase Ib showing engraftment reduction in pathogens

3 Next Generation

Single Strain & Small Molecule

Microba
MAP 315 Phase I IBD
Advancing oncology & autoimmune pipeline

Recent IBD and microbiome deals

Licensee / Acquiror	Licensor / Target	Date	Type	Deal size	Indication / clinical stage
Roche Genentech	roivant	October 2023	Acquisition	Total deal size: US$7.2b	Ulcerative Colitis (Phase 2)
MERCK	Prometheus Biosciences	Apr 2023	Acquisition	Total deal size: US$10.8b	Ulcerative Colitis (phase 2) Crohn's disease (phase 2A) Autoimmune diseases (phase I or pre clinical)
Nestlé HealthScience	Enterome	July 2022	R&D collaboration and license agreement	Total deal size: Undisclosed Upfront: €40m Sales / regulatory milestones: Undisclosed	Food allergies and IBD (pre clinical)
Pfizer	ARENA PHARMACEUTICALS	Mar 2022	Acquisition	Total deal size: US$6.7b	Ulcerative Colitis (phase 3), Crohn's disease (phase2/3), Atopic dermatitis (phase 2 complete)
Roche Genentech	NOVOME BIOTECHNOLOGIES	Nov 2021	R&D collaboration and license agreement	Total deal size: US$605m Upfront: US$15m Additional payments: US$590m	IBD (Discovery)
Nestlé HealthScience	SERES THERAPEUTICS	Jul 2021	Licensing agreement in US/Canada	Total deal size: US$525m Upfront: US$175m Sales / regulatory milestones: Up to US$225m	Recurrent Clostridioides difficile infection (Phase 3)

MICROBA

https://www.roche.com/investors/updates/inv-update-2023-10-23
https://www.merck.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences-inc/
https://www.enterome.com/news-events/enterome-signs-major-strategic-rd-collaboration-with-nestle-health-science-to-develop-and-commercialize-new-allermimics-and-endomimics-immunotherapies-for-food-allergies-and-inflamm/

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals
http://novomebio.com/wp-content/uploads/2021/11/Novome-and-Genentech-Enter-into-Strategic-Collaboration.pdf
https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-nestle-health-science-announce-ser-109-co

Outlook

Upcoming Company Milestones

2023 APR - JUN	2023 JUL - DEC	2024 JAN - MAR
Services New international distribution deals ✓	**Services** New country expansion ✓	**Services** Invivo Clinical integration
Therapeutics - IBD MAP 315 program HREC Approval for Phase I trial ✓	**Services** First Sonic partners operational ●	**Services** Sonic MetaPanel national launch
Therapeutics - IBD MAP 315 program GMP manufacture complete Phase I ✓	**Therapeutics - IBD MAP 315 program** Phase I participant dosing complete ✓	**Therapeutics - IBD MAP 315 program** Phase II clinical trial ready
Therapeutics - IBD MAP 315 program Phase I trial commencement ✓	**Therapeutics - IBD MAP 315 program** Phase I complete ✓	**Therapeutics – IO Program** MOA studies to support candidate selection
	Therapeutics – IO Program Immunological pre-clinical results ✓	**Therapeutics - Autoimmune Program** Stage 2 screening to support Q4 completion
	Therapeutics - Autoimmune Program Stage 1 activity screening complete ✓	

Therapeutic program milestone tracking

Inflammatory Bowel Disease

PHASE I COMPLETE

Recently Completed

- ✓ Phase I HREC approval
- ✓ cGMP manufacturing complete
- ✓ Phase I trial commenced
- ✓ Phase I participant dosing complete
- ✓ Phase I complete

Upcoming milestones

- Phase II readiness

Mount Sinai · Amsterdam UMC University Medical Centers · mater

Immuno-Oncology Program

PRECLINICAL

Recently Completed

- ✓ Leads discovered
- ✓ Leads isolated
- ✓ First animal model results
- ✓ Immunological pre-clinical data

Upcoming milestones

- Lead candidate selection

Garvan Institute of Medical Research · Omico.

Autoimmune Diseases

STAGE 2 SCREENING

Recently Completed

- ✓ Program commenced
- ✓ Strains provided to Ginkgo
- ✓ First in vitro screening results
- ✓ Stage 1 activity screening complete

Upcoming milestones

- Stage 2 activity screening complete

GINKGO BIOWORKS™ THE ORGANISM COMPANY

MICROBA™

Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com

Pasquale Rombola
Chairman
pasquale.rombola@microba.com

CONTACT

Head Office
Level 10, 324 Queen Street
Brisbane QLD Australia

Laboratory
Princess Alexandra Hospital
Woolloongabba QLD Australia

Authorised for release by the Board of Directors